Sign In
Buy EDSA
$6.81
-0.540 (-7.35%)
At Close: Jun 22, 2026
Edesa Biotech Announces $3.5 Million Private Placement of Common Shares Led by CEO and Healthcare-Focused Investors
09:15am, Thursday, 11'th Jun 2026
TORONTO, June 11, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq: EDSA) (the “Company” or “Edesa”), a clinical-stage biopharmaceutical company focused on developing host-directed therape
Edesa Biotech Reports Positive Exploratory Data for Paridiprubart in Patients with Acute Kidney Injury
09:20am, Friday, 05'th Jun 2026
TORONTO, June 05, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq: EDSA), a clinical-stage biopharmaceutical company developing host-directed therapeutics for immuno-inflammatory diseases, today
Edesa Biotech to Present New Data on Paridiprubart in Acute Kidney Injury at European Nephrology Conference
09:15am, Tuesday, 19'th May 2026
TORONTO, May 19, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq: EDSA), a clinical-stage biopharmaceutical company developing host-directed therapeutics for immuno-inflammatory diseases, today a
Edesa Biotech Reports Fiscal 2nd Quarter 2026 Results
04:30pm, Thursday, 14'th May 2026
TORONTO, May 14, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory disease
Edesa Biotech Invited for Oral Showcase at Respiratory Innovation Summit
04:20pm, Tuesday, 31'st Mar 2026
Selection Follows Positive Phase 3 Results for Paridiprubart Demonstrating Statistically Significant Mortality Reductions in ARDS Patients Selection Follows Positive Phase 3 Results for Paridiprubart
Edesa Biotech Advances Vitiligo Program for Planned Mid-2026 Enrollment
09:15am, Thursday, 26'th Mar 2026
TORONTO, March 26, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory disea
Edesa Biotech Reports Additional Positive Results from Phase 3 Paridiprubart Study
09:15am, Tuesday, 24'th Feb 2026
TORONTO, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseas
Market Today: AI Fears Rattle Stocks; CPI Cools, Rivian Pops
05:35pm, Friday, 13'th Feb 2026
Guru Stock PicksRobert Bruce has made the following transactions:Reduce in NEE by 1.49%Ray Dalio has made the following transactions:Reduce in CNX by 13.43%Sold
Edesa Biotech Reports Fiscal 1st Quarter 2026 Results
04:20pm, Friday, 13'th Feb 2026
TORONTO, Feb. 13, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseas
Market Today: Tech Slumps, Broadcom Tanks; EU Eases ICE Ban
05:35pm, Friday, 12'th Dec 2025
Stock News Tech-led selloff caps tough week: US stocks fell as investors rotated out of mega-cap tech after Broadcom (AVGO) and Oracle (ORCL) stoked AI-spending
Edesa Biotech Reports Fiscal Year 2025 Results
04:20pm, Friday, 12'th Dec 2025
TORONTO, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseas
Edesa Biotech Announces Upcoming Conference Schedule
04:30pm, Friday, 31'st Oct 2025
TORONTO, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseas
Edesa Biotech Reports Positive Results in Phase 3 Respiratory Study
07:45am, Tuesday, 28'th Oct 2025
TORONTO, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics (HDTs) for immuno-inflammatory
Edesa Biotech Posts Narrower Loss in Q3
04:49pm, Friday, 08'th Aug 2025
Edesa Biotech Posts Narrower Loss in Q3
Edesa Biotech Reports Fiscal 3rd Quarter 2025 Results
04:35pm, Friday, 08'th Aug 2025
TORONTO, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseas
